Results 201 to 210 of about 2,967,291 (296)

Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? [PDF]

Oncologist
Alfieri S, Romanò R, Marceglia S, De Giorgi V, Peris K, Sollena P, Piccerillo A, Moro R, Gualdi G, Ascierto PA, Palla M, Paone M, Eibenschutz L, Spagnolo F, Queirolo P, Filippini DM, Cavalieri S, Resteghini C, Bergamini C, Manocchio A, Licitra L, Bossi P.   +21 more
europepmc   +1 more source

Re‐Awakening Public Attention to the Silent Pandemic of Cancer Among Older Adults in Low‐ and Middle‐Income Countries

Aging and Cancer, EarlyView.
ABSTRACT As global populations age, cancer is increasingly becoming a leading cause of morbidity and mortality among older adults, particularly in low‐ and middle‐income countries (LMICs). Despite accounting for the majority of new cancer cases and deaths, older individuals remain underrepresented in cancer research, clinical guidelines, and health ...
Ibrahim Bidemi Abdullateef, Sunkanmi Folorunsho, Abdulazeez Opeyemi Abdulganiyu   +2 more
wiley   +1 more source

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

Aging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss, Alexis C. Wardell, Allison M. Deal, Kirsten A. Nyrop, Allison Ross, Yara G. Abdou, Jeffrey D. Aldrich, Lisa A. Cary, E. Claire Dees, Katherine E. Reeder‐Hayes, Emily M. Ray, Natalia Mitin, Denis Tsygankov   +12 more
wiley   +1 more source

Clinical complete response after trastuzumab deruxtecan 6th-line treatment for postoperative gastric cancer recurrence: a case report. [PDF]

Surg Case Rep
Yamada E, Iwasaki K, Barroga E, Sakurai T, Enomoto M, Shimoda Y, Mazaki J, Kuwabara H, Hoshino A, Hayashi Y, Ishizaki T, Nagakawa Y.   +11 more
europepmc   +1 more source

Impact of clinical complete response on treatment outcomes in patients with locally advanced HPV-negative oropharyngeal squamous cell carcinoma. [PDF]

J Cancer Res Clin Oncol, 2020
De Felice F, Musio D, Abate G, Moscarelli E, Bulzonetti N, Tombolini V.   +5 more
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED). [PDF]

Intern Med
Suzuki N, Odawara N, Fujisawa G, Ishibashi R, Hata M, Oya Y, Tamada K, Hayashi T, Abe S, Miyakawa Y, Hayakawa Y, Shinozaki-Ushiku A, Ushiku T, Boku N, Fujishiro M.   +14 more
europepmc   +1 more source

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai, Yang Qu, Reziya Abuduxukuer, Kejia Zhang, Peng Zhang, Xin Tang, Huaimei Zhang, Lijuan Wang, Lichong Yang, Shuangxu Tan, Zhimei Yuan, Ce Han, Lili He, Yuping Zheng, Fenglan Zhao, Lijie Guo, Ligang Jiang, Jinfeng Li, Yongfei Jiang, Xuexia Zou, Dan Xu, Han Xu, Xiaojia Wang, Yingbin Qi, Xuefeng Hu, Yu Zhang, Zhen‐Ni Guo, Hang Jin, on behalf of the Biomarkers of Brain Injury Investigator Study Group   +28 more
wiley   +1 more source

Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial. [PDF]

Front Oncol
Scardina L, Masetti R, Franceschini G.
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source